Global Artificial Intelligence Rules Are Coming Fast And Out Of Sync
A breakthrough AI diagnostic passes FDA review but triggers high-risk classification in Europe. The same algorithm, trained on global datasets, is rejected by China's regulators. As AI medical device rules fracture across borders, SaMD startups discover that regulatory approval in one market guarantees nothing elsewhere.
Why Your Regulatory Strategy Feels Like A Shot In The Dark
Fragmented guidance documents, trial outcomes, and device data don’t just slow down strategy—they distort it. When regulatory plans ignore the full picture, startups risk repeating errors or overlooking key signals. Smart teams are connecting the dots before their next submission is even in draft.